Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-01

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to severe evaporative DED after a treatment for 30 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye

NCT07050446

Dry Eye Disease (DED)

COMPLETED PHASE3

A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

NCT03368404

Dry Eye

COMPLETED NA

A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye

NCT01791426

Dry Eye

WITHDRAWN NA

Efficacy of Lipid-containing Artificial Tears in the Treatment of Dry Eye

NCT06955585

Dry Eye Disease Dry Eye Dry Eye, Evaporative

NOT_YET_RECRUITING NA

A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

NCT02975102

Dry Eye

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multi-centre, randomised, parallel-group, controlled (placebo), double-blind study

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

As the clinical trial will be conducted in a double-blind way, both investigators and patients will be blind with respect to the treatment administered. For the purpose of individual unblinding of a patient's treatment the investigator will receive a sealed emergency envelope for each patient containing the treatment code (Only in case of medical emergency it is permitted to open the emergency envelope).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vizol S LIPID BALANCE

topical administration of 1 drop of Vizol S LIPID BALANCE in each eye 4 times a day for 30 days

Group Type EXPERIMENTAL

Vizol S LIPID BALANCE eye drops

Intervention Type DRUG

1 drop 4 times a day

ophthalmic saline eyedrops

topical administration of 1 drop of ophthalmic saline eye drops matching Vizol S LIPID BALANCE in each eye 4 times a day for 30 days

Group Type PLACEBO_COMPARATOR

ophthalmic saline eye drops

Intervention Type DRUG

1 drop 4 times a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vizol S LIPID BALANCE eye drops

1 drop 4 times a day

Intervention Type DRUG

ophthalmic saline eye drops

1 drop 4 times a day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Test Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* use of eyelid hygiene for at least 14 days prior to screening
* diagnosis of moderate to severe dry eye disease (DED), with an Ocular Surface Disease Index (OSDI) score ≥23
* Tear Film Break-Up Time (TFBUT) \<10 seconds in one or both eyes
* Meibomian gland expression of grade 2 or higher in both eyes
* written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the patients participating in the clinical trial

Exclusion Criteria

* intolerance or hypersensitivity to any component of the Investigational Product (IPs)
* ocular or intraocular surgery or serious ocular trauma ≤6 months before enrolment
* current punctal occlusion of any type
* use of concomitant topical ocular medications within 24 hours prior to first intended administration of the IPs (except for artificial tears or lubricants; previously used artificial tears or lubricants must be suspended for the duration of the study)
* use of systemic medications that may contribute to dry eye (unless on a stable regimen for ≥30 days before screening and throughout the study)
* current or previous topical treatment of the eye with antibiotics, steroids or cyclosporin A within the last four weeks
* ocular or systemic infections or conditions (e.g., epithelial herpes simplex keratitis, vaccinia, varicella, or mycobacterial infection, fungal disease, iritis) or other relevant ocular pathology judged by the investigator that preclude safe administration of the IPs
* use of contact lenses within 1 week before screening and throughout the study
* active ocular disease other than DED or any other acute or chronic disease which may interfere with the aims of the clinical trial
* history of severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator
* diagnosis of Corona Virus Disease (COVID-19) within the last 14 days prior to individual enrolment of the patient
* contact to persons in international risk areas for COVID-19 as defined by the Institute of Public Health of Serbia within the last 14 days prior to individual enrolment of the patient
* known direct contact with insufficient protection to persons with diagnosis of COVID-19 within the last 14 days prior to individual enrolment upon reporting of the patient
* history of or current drug or alcohol dependence
* participation in an investigational drug or device study ≤30 days before screening
* positive pregnancy test at screening examination
* pregnant or lactating women
* female patients who do not agree to apply highly effective contraceptive methods (highly effective contraceptive methods are defined in chapter 13.2.1)
* patients suspected or known not to follow instructions
* patients who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes